Quick Takeaways: Why It Matters? With 138 horses across eight practices showing significantly better outcomes and nearly triple the odds of returning to prior performance, the data should help veterinarians justify using equicenta CTM as a convenient, regenerative alternative to harvesting...
Quick Takeaways: Why It Matters? By terminating the PrecisePRP arrangement with VetStem, PetVivo removes outstanding invoices, royalties and milestone overhangs from a non-core product line, which should simplify the story for investors and management while freeing attention and capital fo...
Quick Takeaways: Why It Matters? CT-RevitL positions Enovis’s Companion Animal Health business to deepen its role in technology-enabled, non-drug pain and mobility management, giving clinics a more standardized, high-powered PBM platform that can turn laser therapy into a recurring, protoc...
Quick Takeaways: Why It Matters? Akston could emerge as a serious competitor in the fast-growing anti‑NGF OA segment that Zoetis currently leads with its once‑monthly monoclonal. Because Akston’s Ambifect approach stimulates sustained endogenous anti‑NGF antibody responses, AKS‑548d remain...
Quick Takeaways: Why It Matters? This partnership is designed to scale Rebound High Performance PRP across the US veterinary market by combining epiq’s distribution reach with Vetirus’s product and regulatory credentials, removing a key barrier to adoption-access to e...
Quick Takeaways Why It Matters? Gallant is on track to create one of the first mass‑market, disease‑modifying OA biologics in companion animals, shifting regenerative medicine from niche referral centers into everyday general practice via a simple, ready‑to‑use IV product. ...
Quick Takeaways: Why It Matters? Genflow’s early canine SIRT6 data are strong enough that big animal‑health players now want a closer look, but not yet strong enough for anyone to sign a deal. The expanded web of NDAs suggests real strategic interest ...
Quick Takeaways: Why It Matters? The partnership gives Gallant industrial‑grade cold-chain logistics, solving a key bottleneck for scaling allogeneic cell therapies beyond a few specialty centers. For MWI/Cencora, establishing -80°C capability positions the ...
